Armistice AUM Growth Reflects Strategic Focus on Healthcare Innovation and Biotech Advancement
Recent investment activities reveal a concentrated effort by Armistice Capital to build significant positions across specialized healthcare sectors, with particular emphasis on ophthalmology, women's health technologies, and biotechnology developments. The firm's portfolio expansion demonstrates a calculated approach to identifying promising medical innovations and therapeutic solutions. In the ophthalmic sector, Armistice Capital's strategic positioning became evident through several key transactions. A notable investment emerged in the third quarter of 2023, when the firm acquired a substantial stake in Eyenovia, securing over 3 million shares representing approximately 8.08% ownership. This investment supports Eyenovia's development of specialized ophthalmic products, including their
Read More